Navigation Links
Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
Date:6/21/2009

SEATTLE, June 22 /PRNewswire-FirstCall/ --

Updated follow-up phase III EXTEND (PIX 301) clinical trial data enhances previously reported superior response rates for pixantrone over comparator including in high risk patient subgroups

Additional Clinical Studies Also Highlighted at Pan Pacific Conference

  • Randomized phase III; PIX 302-Pixantrone plus rituximab significantly improves CR rate (35% vs. 11%), ORR (75% vs. 33%) and time to progression (TTP) (13.2 vs. 8.1 months) compared to rituximab alone in relapsed indolent NHL
  • Phase II; AZA I06- Pixantrone plus fludarabine, and rituximab (FPD-R regimen) produces high CR/CRu (70%) and ORR (89%) in multiple relapsed indolent NHL

Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that an overview of CTI's pixantrone clinical studies in aggressive and indolent NHL including follow-up data and subgroup analyses of high risk patients from the phase III EXTEND PIX 301 clinical trial of pixantrone (the "PIX 301 EXTEND trial") is being presented at the Pan Pacific Lymphoma conference by Dr. Richard Van der Jagt of the Ottawa General Hospital.

Pixantrone PIX 301 EXTEND Trial Follow-up Data and Subgroup Analyses

Initial follow-up data in the PIX 301 EXTEND trial demonstrated that three additional patients in the pixantrone arm achieved a CR and one additional patient achieved a CRu during the follow-up period of patients that received chemotherapy on the control arm. Including the treatment and follow-up period, pixantrone had a significantly higher complete remission rate compared to the patients who received standard chemotherapy (CR/CRu rate=24% (17 of 70 patients) for pixantrone vs. CR/CRu rate=7% (5 of 70 patients) for standard chemotherapy; p=0.009). No patient in the standard chemotherapy
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
4. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
5. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
6. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
9. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
10. AHF Seeks White House Clarification After Press Room Flap Over CDCs HIV Numbers
11. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Belgium, December 12, 2011 The peer ... of a clinical trial demonstrating the sedative action of the ... whose abstract is available from the US National Libretry of ... http://www.ncbi.nlm.nih.gov/pubmed/22035386 The results show, ...
... FRANCISCO, Calif., Dec. 10, 2011  Onyx Pharmaceuticals, Inc. (Nasdaq: ... poster presentations of single-agent carfilzomib, a next generation proteasome ... at the 53rd American Society of Hematology (ASH) Annual ... expanded data set supports our belief in the potential ...
Cached Medicine Technology:Insomnia: A No-Drug Solution? 2Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 2Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 3Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 4Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 5Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 6
(Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
(Date:4/23/2014)... methods that can rapidly screen a large cell ... inside that population has been seriously lacking," said ... the Royal Society of Chemistry journal Chemical ... his coworkers have developed a novel technique that ... Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ...
(Date:4/23/2014)... as the United States, it may come as a surprise ... adequate food due to lack of money or other financial ... the University of Illinois using data from the National Health ... are dealing with hunger are also facing negative health and ... over age 60 faced the threat of hungerthat translates to ...
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
(Date:4/23/2014)... has been a rapidly evolving pursuit with many ... in the research road, scientists have found a ... with the disease. The report, which appears in ... have important implications for developing novel treatments. , ... that for years, research has suggested a link ...
Breaking Medicine News(10 mins):Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... a recent study that came out in the journal Environmental ... plastics on human beings. ,Bisphenol-A (BPA) is a ... grade materials for making air tight containers, drinking water bottles, ... of Medicine did the study to find out about the ...
... that spreads through mosquito bites, among other things, did not ... of Nature Medicine scientists have shown a successful treatment on ... developed an antibody that can successfully fight the virus. The ... naturally against this virus and in turn never get affected ...
... study made by researchers of UK, scientists have found that ... the blood of the passengers. ,The study was done ... today, do have any effect on the health of the ... peripheral oxygen saturation and pulse rate of 84 passengers, aged ...
... cure people suffering from hay fever by teaching them self-hypnosis.//,The ... curing allergic reactions. 79 patients of an average age of ... or pollen were taken in the study. All these people ... years. Random parallel group was used as control for the ...
... to be a risk factor for multiple sclerosis. New ... more in people suffering from multiple sclerosis. ,In ... of medicine, researchers had been able to associate habitual ... sclerosis. In a study comprising of 201 cases of ...
... addiction is a problem because the addicts find it hard ... this type of behavior may be that drugs affect the ... towards other rewards of life, like eating and fulfilling of ... treat drug addiction may be a surgical procedure by which ...
Cached Medicine News:
Cold light source triple outlet....
With the LX300, you don't have to compromise the quality of your lighting system to meet your budget needs. You get the best and whitest light possible from an affordable 300 Watt light source....
The Carl Zeiss Head-worn Loupes L and LC are the ideal solution if a low magnification suffices for your work and you want to keep your hands free to perform the task at hand....
Head-worn Loupe KF Titanium the teleloupe system is mounted on a special frame with straight temples and an elastic headband....
Medicine Products: